Log In
Print
BCIQ
Print
Print this Print this
 

tesevatinib (KD019, XL647)

  Manage Alerts
Collapse Summary General Information
Company Symphony Evolution Inc.
DescriptionReversible tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2; KDR/Flk-1), VEGFR-3, and epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionKinase inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today